Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $59.16, for a total transaction of $177,480.00. Following the sale, the insider now owns 183,571 shares of the company’s stock, valued at $10,860,060.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Clovis Oncology, Inc. (NASDAQ CLVS) opened at $54.48 on Thursday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. The stock has a market cap of $2,715.91, a P/E ratio of -6.58 and a beta of 1.39. Clovis Oncology, Inc. has a one year low of $45.42 and a one year high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.06). The business had revenue of $16.81 million during the quarter, compared to analyst estimates of $21.12 million. Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. During the same quarter last year, the firm earned ($1.70) earnings per share. equities research analysts predict that Clovis Oncology, Inc. will post -7.65 EPS for the current fiscal year.

CLVS has been the subject of several research reports. Zacks Investment Research cut shares of Clovis Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Oppenheimer restated a “hold” rating on shares of Clovis Oncology in a report on Tuesday, October 10th. Barclays initiated coverage on shares of Clovis Oncology in a report on Monday, October 23rd. They set an “overweight” rating and a $105.00 price target for the company. Morgan Stanley decreased their price target on shares of Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Finally, Stifel Nicolaus restated a “buy” rating and set a $125.00 price target on shares of Clovis Oncology in a report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company. Clovis Oncology has a consensus rating of “Hold” and an average target price of $90.43.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Clovis Oncology by 10.2% in the second quarter. Vanguard Group Inc. now owns 3,618,843 shares of the biopharmaceutical company’s stock valued at $338,831,000 after acquiring an additional 333,648 shares during the last quarter. Orbimed Advisors LLC lifted its stake in Clovis Oncology by 13.5% in the third quarter. Orbimed Advisors LLC now owns 2,388,670 shares of the biopharmaceutical company’s stock valued at $196,826,000 after acquiring an additional 284,300 shares during the last quarter. State Street Corp lifted its stake in Clovis Oncology by 4.3% in the second quarter. State Street Corp now owns 1,943,480 shares of the biopharmaceutical company’s stock valued at $181,966,000 after acquiring an additional 80,171 shares during the last quarter. Farallon Capital Management LLC lifted its stake in Clovis Oncology by 662.5% in the second quarter. Farallon Capital Management LLC now owns 610,000 shares of the biopharmaceutical company’s stock valued at $57,114,000 after acquiring an additional 530,000 shares during the last quarter. Finally, Samlyn Capital LLC lifted its stake in Clovis Oncology by 131.8% in the second quarter. Samlyn Capital LLC now owns 567,700 shares of the biopharmaceutical company’s stock valued at $53,154,000 after acquiring an additional 322,800 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/01/18/gillian-c-ivers-read-sells-3000-shares-of-clovis-oncology-inc-clvs-stock.html.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.